Published in Vaccine Weekly, September 3rd, 2008
"We'd characterize VaxInnate's M2e universal influenza vaccine candidate as very promising, based upon the immune responses and tolerability we saw in the clinical trial participants," said Christine Turley, MD, Director of clinical trials and clinical research at the Sealy Center for Vaccine Development, University of Texas Medical Branch (UTMB), and the study's primary investigator. "UTMB is committed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.